Abstract
Peripheral artery disease is characterized by reduced blood flow to the lower limb, resulting in chronic ischemia in these muscles, which can lead to eventual amputation of the affected limb. Stimulation of angiogenesis in the ischemic region would be of therapeutic benefit; however, attempts to increase angiogenesis through delivery of vascular endothelial growth factor (VEGF) largely have been unsuccessful. Recent studies have shown that VEGF signaling through its receptors, VEGFR1 and VEGFR2, is much more complex than previously appreciated. This review will examine current research into the function of VEGFR1 and -2 signaling pathways, and evidence of cross-talk between these two receptors. The potential impact of endothelial cell co-stimulation via other growth factors/cell surface receptors (such as angiopoietins and ephrins) on angiogenesis also will be discussed. Evidence suggesting deficiencies in VEGF pathway signaling in individuals with chronic ischemia and diabetes will be discussed. Numerous pro-angiogenic therapies for ischemia have been employed. The successes and limitations of these therapies will be illustrated, emphasizing more recent angiogenesis therapies that focus on activating co-ordinated patterns of pro-angiogenic genes as the most promising direction in the treatment of ischemic muscle tissue in peripheral artery disease.
Keywords: Angiogenesis, VEGF signaling, VEGF receptors, ischemia, diabetes, therapies
Current Pharmaceutical Design
Title: Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle
Volume: 15 Issue: 4
Author(s): C. Uchida and T. L. Haas
Affiliation:
Keywords: Angiogenesis, VEGF signaling, VEGF receptors, ischemia, diabetes, therapies
Abstract: Peripheral artery disease is characterized by reduced blood flow to the lower limb, resulting in chronic ischemia in these muscles, which can lead to eventual amputation of the affected limb. Stimulation of angiogenesis in the ischemic region would be of therapeutic benefit; however, attempts to increase angiogenesis through delivery of vascular endothelial growth factor (VEGF) largely have been unsuccessful. Recent studies have shown that VEGF signaling through its receptors, VEGFR1 and VEGFR2, is much more complex than previously appreciated. This review will examine current research into the function of VEGFR1 and -2 signaling pathways, and evidence of cross-talk between these two receptors. The potential impact of endothelial cell co-stimulation via other growth factors/cell surface receptors (such as angiopoietins and ephrins) on angiogenesis also will be discussed. Evidence suggesting deficiencies in VEGF pathway signaling in individuals with chronic ischemia and diabetes will be discussed. Numerous pro-angiogenic therapies for ischemia have been employed. The successes and limitations of these therapies will be illustrated, emphasizing more recent angiogenesis therapies that focus on activating co-ordinated patterns of pro-angiogenic genes as the most promising direction in the treatment of ischemic muscle tissue in peripheral artery disease.
Export Options
About this article
Cite this article as:
Uchida C. and Haas L. T., Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle, Current Pharmaceutical Design 2009; 15 (4) . https://dx.doi.org/10.2174/138161209787315800
DOI https://dx.doi.org/10.2174/138161209787315800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Current Pharmaceutical Design The Cardiovascular Protective Effects of Chrysin: A Narrative Review on Experimental Researches
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Metabolic Syndrome and Myocardial Infarction in Women
Current Pharmaceutical Design Cutaneous Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews A Narrative Review of Recent Studies on the Role of Vitamin D in the Prevention of Cardiac and Renal Risk and Additional Considerations for COVID-19 Vulnerability
Current Vascular Pharmacology Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology